FAQ

MORAb-009 monoclonal antibody

Known as: MORAb-009 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2015
02420072015

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies

Narrower (1)

amatuximab
mesothelin

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
MORAb-009 monoclonal antibody
Monoclonal Antibodies
mesothelin
amatuximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
OBJECTIVES To investigate the effect of the injection dose of MORAb-009 (amatuximab, an anti-mesothelin monoclonal antibody), the… (More)
Is this relevant?
2012
2012
Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
Mesothelin is a tumor differentiation antigen that is highly expressed in many epithelial cancers, with limited expression in… (More)
Is this relevant?
2012
2012
Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.
The mesothelin-specific monoclonal antibody MORAb-009 is capable of blocking the binding of mesothelin to CA-125 and displays… (More)
Is this relevant?
Review
2012
Review
2012
Novel therapies in phase II and III trials for malignant pleural mesothelioma.
Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the desperate need to develop better… (More)
Is this relevant?
2012
2012
Structure of mesothelin and therapeutic antibody complex
Background: Mesothelin is a tumor differentiation antigen; its binding to tumor-antigen CA-125 can lead to tumor metastasis… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
INTRODUCTION Radiolabeling of a monoclonal antibody (mAb) with a metallic radionuclide requires the conjugation of a bifunctional… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
PURPOSE MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2010
2010
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
BACKGROUND Mesothelin, a tumor differentiation antigen highly expressed in mesothelioma and ovarian cancer, is the receptor for… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Cancer Therapy: Clinical Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Purpose: MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2007
2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Novel therapeutic agents that are safe and effective are needed for the treatment of pancreatic, ovarian, lung adenocarcinomas… (More)
Is this relevant?